Current Neuro-Oncology

Volume 27 Number 35
20 December 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 35, 20 December

Castellino RC, Mumme HL, Franson AT, Yu B, Robinson MH, Dhodapkar K, Aguilera D, Schniederjan MJ, Keesari R, He Z, Bhasin M, Priebe W, Heimberger AB, MacDonald TJ.
First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients.
JCI Insight. 2025 Dec 11:e194823. doi: 10.1172/jci.insight.194823. PMID: 41379553. Interventional study. ˍ

Rocha Grade D, Soares T, João DA, Lima T, Marques Baptista A.
Extremely Long-Term Glioblastoma Survival (Ten Years): A Possible Role of Immune Modulation From Pre-existing Diseases.
Cureus. 2025 Dec 11;17(12):e98984. doi: 10.7759/cureus.98984. PMID: 41523441. ˍ

Guo C, Yang Q, Deng M, Qiu X, Wu S, Du X, Sai K, Dai Z, Chen Z, Zhang J, Lin F, Ke C, Xi S, Hu W, Zhou Z, Li J, Cao X, Liao Y, Lv Y, Brown D, Langlands J, Johnson G, Bacha J, Kwan C, Kanekal S, Schwartz R, Chen Z.
VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.
Discov Oncol. 2025 Dec 12. doi: 10.1007/s12672-025-04235-y. PMID: 41385182. Interventional study. ˍ

Sincu A, Orasanu CI, Voda RI, Bosoteanu M, Enciu M, Vamesu S, Ghitoi SA, Deacu M.
Unpredictable Evolution of Pilocytic Astrocytoma in Adults: A Case Series and Diagnostic Challenges.
Am J Case Rep. 2025 Dec 12;26:e947774. doi: 10.12659/AJCR.947774. PMID: 41382984. Case report. ˍ

Xu Y, Zhou J, Zhou X, Li Y, Yang S, Xue Z.
Comprehensive analysis of clinical, pathological, and molecular risk factors affecting the prognosis of patients with glioma.
Medicine (Baltimore). 2025 Dec 12;104(50):e46442. doi: 10.1097/MD.0000000000046442. PMID: 41398783. Observational study. ˍ

Matsuyama T, Yamada S, Otsuka H, Watakabe T, Fukugawa Y, Oya N.
Adaptive radiation therapy for glioblastoma: clinical efficacy and recurrence patterns.
Radiat Oncol. 2025 Dec 13. doi: 10.1186/s13014-025-02778-6. PMID: 41390433. Observational study. ˍ

Tian X, Sun B, Cheng H, Hao X, Sun G, Hao J, Chen L.
Combined 5-Aminolevulinic Acid Fluorescence and Intraoperative Ultrasound Enhance Resection and Functional Outcomes in High-Grade Glioma Surgery.
Photodiagnosis Photodyn Ther. 2025 Dec 13:105316. doi: 10.1016/j.pdpdt.2025.105316. PMID: 41397640. Observational study. ˍ

Krotkova OA, Galkin MV, Danilov GV, Enikolopova EV, Kaverina MY, Kuleva AY, Filchenkova NA, Amelchenko EM, Anokhin KV, Lazutkin AA, Enikolopov G.
Delayed, transient, lateralized deficits in pattern separation and pattern completion after focal hippocampal irradiation in humans.
Sci Rep. 2025 Dec 15;15(1):43846. doi: 10.1038/s41598-025-29852-z. PMID: 41398354. Longitudinal study. ˍ

Tong Y, Rao H, Li Y, Chang C, Yang Y.
Efficacy and survival outcomes of bevacizumab plus minocycline for glioblastoma.
Am J Transl Res. 2025 Dec 15;17(12):9846-9858. doi: 10.62347/LDSW5672. PMID: 41552322. ˍ

van Hout L, van den Elzen FEL, de Jong Z, Grun N, Broen MPG, Bartelink I, Bruynzeel AME, Lagerwaard FJ, Buter J, Vandertop WP, Westerman BA, Lissenberg-Witte BI, Kouwenhoven MCM.
Recurrent Hematological Toxicity After Second-Line Treatment in Patients with Glioblastoma: Indication of a Potential Predisposition.
Oncologist. 2025 Dec 15:oyaf411. doi: 10.1093/oncolo/oyaf411. PMID: 41397909. Observational study. ˍ

Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, Batchelor TT, Berger TR, Beroukhim R, Chukwueke U, Dietrich J, Forst DA, Gerstner ER, Castro LNG, Jordan JT, Mcfaline-Figueroa JR, Lee EQ, Nayak L, Nakhate V, Ospina JP, Plotkin SR, Wang N, Rhee JY, Reardon DA, Wen PY.
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma.
Neuro Oncol. 2025 Dec 15:noaf287. doi: 10.1093/neuonc/noaf287. PMID: 41397912. Observational study˰ ˍ

Lei S, Li C, Wang J, Zheng R.
Global patterns and trends in brain and central nervous system tumors incidence by histological subtype in 185 Countries in 2022: a population-based study.
Int J Surg. 2025 Dec 16. doi: 10.1097/JS9.0000000000004417. PMID: 41405297. Observational study. ˍ

Whalley K.
Neural excitability promotes glioma growth.
Nat Rev Neurosci. 2025 Dec 16. doi: 10.1038/s41583-025-01017-x. PMID: 41402625. Commentary˰ ˍ
COMMENT ON
McAlpine H, Rosier M, Rozario J, Wang X, Wimmer VC, Guzulaitis R, Guan H, Hu Y, Chirlov L, Davey C, Finch S, Drummond KJ, Palmer LM.
Increased neural excitability and glioma synaptic activity drives glioma proliferation in human cortex.
Nat Neurosci. 2025 Nov 26. doi: 10.1038/s41593-025-02149-0. PMID: 41298888. Laboratory investigation. ˍ

Youngblood MW, Kumari A, Kang YT, Gould A, Habashy K, Gomez M, Lingamarla H, Morey T, Chen L, Congivaram H, Ward R, Zhang H, Sears TK, McCortney K, Pituch KC, Torres Ponce EM, Zarrieneh A, Nieves M, Vandermolen S, Primdahl D, Dixit K, Lukas RV, Kumthekar P, Dmello C, Bouchoux G, Canney M, Amidei C, Stupp R, Nagrath S, Sonabend AM.
Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.
Nat Commun. 2025 Dec 16;16(1):11045. doi: 10.1038/s41467-025-65681-4. PMID: 41402297. Interventional study.

Lachance DH, Decker PA, Kollmeyer TM, Drucker KL, Praska CE, Kosel ML, Odukoya AA, Kizilbash SH, Maqbool MA, Shafqat S, Tobin WO, Parney IF, Burns TC, Galanis E, Giannini C, Vaubel RA, Ida CM, Jenkins RB, Eckel-Passow JE.
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH-wildtype.
Neurooncol Adv. 2025 Dec 17;8(1):vdaf260. doi: 10.1093/noajnl/vdaf260. PMID: 41908146. Observational study. ˍ

Lawrence L.
Diffuse midline gliomas get first FDA-approved drug.
Cancer. 2025 Dec 17;131(24):e70146. doi: 10.1002/cncr.70146. PMID: 41405355. News. ˍ

Zhu M, Yang M, Li R, Hu X, Chen J, Xu L, Chen S, Li T, Wang J, Zheng B, He H.
Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment.
Nat Commun. 2025 Dec 18. doi: 10.1038/s41467-025-67415-y. PMID: 41413041. Laboratory investigation. ˍ

Grosu AL, Weber WA, Graf E, Mix M, Nestle U, Schimek-Jasch T, Wiehle R, Mader I, Würtemberger U, Langen KJ, Niyazi M, Paulsen F, König L, Giordano FA, Spehl I, Bernhardt D, Schymalla MM, Pöttgen C, Semrau S, Brunner T, Hültenschmidt B, Krause BJ, Ciernik IF, Beck J, Baumert BG, Meyer PT, Urbach H, Popp I; GLIAA Study Group.
O-(2-[¹⁸F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial.
Lancet Oncol. 2025 Dec 19:S1470-2045(25)00642-4. doi: 10.1016/S1470-2045(25)00642-4. PMID: 41429128. Interventional study. ˍ